Table 2.
Baseline demographic and clinical characteristics of 3 study cohorts.
| Characteristics | Monotherapy group (n = 116) | Chemo group (n = 28) | Immune group (n = 33) | p-value | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Sex | 0.234 | ||||||
| Men | 62 | 53.4 | 17 | 60.7 | 23 | 69.7 | |
| Women | 54 | 46.6 | 11 | 39.3 | 10 | 30.3 | |
| Age(years) | 0.135 | ||||||
| Median (range) | 61 (32–82) | 60.5 (36–71) | 51 (33–71) | ||||
| <65 | 74 | 63.8 | 20 | 71.4 | 27 | 81.8 | |
| ≥65 | 42 | 36.2 | 8 | 28.6 | 6 | 18.2 | |
| Site of primary disease* | 0.015 | ||||||
| Left-sided | 47 | 40.5 | 12 | 42.9 | 23 | 69.7 | |
| Right-sided | 22 | 19 | 8 | 28.6 | 6 | 18.2 | |
| Rectum | 47 | 40.5 | 8 | 28.6 | 4 | 12.1 | |
| Gene mutation status | 0.665 | ||||||
| RAS/BRAF wild-type | 58 | 50.0 | 12 | 42.9 | 14 | 42.4 | |
| RAS mutant | 57 | 49.1 | 14 | 50.0 | 17 | 51.5 | |
| BRAF mutant | 2 | 1.7 | 1 | 3.6 | 2 | 6.1 | |
| MMR status | 0.658 | ||||||
| pMMR | 114 | 98.3 | 28 | 100 | 32 | 97.0 | |
| dMMR | 2 | 1.7 | 0 | 0 | 1 | 3.0 | |
| Site of metastases† | 0.798 | ||||||
| Lung limited | 22 | 19.0 | 5 | 17.9 | 8 | 24.2 | |
| Liver limited | 53 | 45.7 | 14 | 50.0 | 10 | 30.3 | |
| Liver and lung | 23 | 19.8 | 5 | 17.9 | 8 | 24.2 | |
| Other | 18 | 15.5 | 4 | 14.3 | 7 | 21.2 | |
| Primary tumor resection | 0.652 | ||||||
| Yes | 99 | 85.3 | 25 | 89.3 | 30 | 90.9 | |
| No | 17 | 14.7 | 3 | 10.7 | 3 | 9.1 | |
| Treatment line of regorafenib | 0.148 | ||||||
| Third-line | 76 | 65.5 | 21 | 75 | 17 | 51.5 | |
| Forth or late-line | 40 | 34.5 | 7 | 25 | 16 | 48.5 | |
| Previous biologics treatment# | |||||||
| anti-EGFR | 42 | 36.2 | 11 | 39.3 | 12 | 36.4 | 0.954 |
| anti-VEGF | 92 | 79.3 | 20 | 71.4 | 26 | 78.8 | 0.660 |
| Starting dose(mg) | 0.901 | ||||||
| 80 | 63 | 54.3 | 14 | 50.0 | 17 | 51.5 | |
| 120 | 53 | 45.7 | 14 | 50.0 | 16 | 48.5 | |
| Final dose(mg) | 0.460 | ||||||
| ≤80 | 104 | 81.9 | 24 | 85.7 | 27 | 78.8 | |
| 120 | 12 | 10.3 | 4 | 14.3 | 6 | 18.2 | |
pMMR, proficient mismatch repair; dMMR, deficient mismatch repair.
Bold values indicate p < 0.05.
*Right-sided included tumors from cecal to two thirds of proximal transverse colon; left-sided represented tumors from one third of distal transverse colon to rectum (not including rectum).
†According to the site of metastases, patients were divided into four groups: (1) liver limited MET; (2) lung limited MET; (3) liver and lung MET (4) other MET.
#Anti-EGFR, Cetuximab or panitumumab; Anti-VEGF, Bevacizumab.